论文部分内容阅读
目的:探讨健脾益胃方治疗消化性溃疡(Peptic Ulcer,PU)的疗效及药物作用机理。方法:60例PU患者随机分为对照组,观察组各30例。对照组:给予奥美拉唑抑酸治疗;观察组:在奥美拉唑抑酸治疗的基础上给予健脾益胃方治疗。8周后,观察两组患者临床疗效及胃酸、胃泌素、生长抑素的改变情况。结果:治疗组治疗后临床有效率达90%,而治疗后对照组有效率仅达66.6%,两组具有显著统计学差异(P<0.05),治疗后治疗组与治疗前治疗组相比,降低胃酸(PH值)、减少胃泌素分泌、促进生长抑素分泌具有统计学差异(P<0.05);治疗后治疗组与治疗后对照组相比,降低胃酸(PH值)、减少胃泌素分泌、促进生长抑素分泌具有统计学差异(P<0.05)。结论:健脾益胃方能够改善消化性溃疡患者临床症状及其作用机理可能与抑制消化性溃疡胃酸、胃泌素的过度分泌和提高生长抑素分泌相关,该方药具有一定程度临床推广价值。
Objective: To investigate the therapeutic effect of Peptic Ulcer (PU) and its mechanism of action by using Jianpi Yisi decoction. Methods: Sixty patients with PU were randomly divided into control group and observation group of 30 cases. Control group: given omeprazole acid suppression treatment group: observation group: omeprazole acid suppression therapy based on the spleen and stomach treatment. After 8 weeks, the clinical efficacy and changes of gastric acid, gastrin and somatostatin in both groups were observed. Results: The effective rate of the treatment group after treatment was 90%, while the effective rate of the control group was only 66.6% after treatment, with significant difference between the two groups (P <0.05). After treatment, compared with the pretreatment group, Reduce the gastric acid (PH value), reduce the secretion of gastrin and promote the secretion of somatostatin (P <0.05). After treatment, the treatment group compared with the control group, reduce the gastric acid (PH), reduce gastrin There was a significant difference in the secretion of somatostatin and secretion of somatostatin (P <0.05). Conclusion: Jianpi Yisuifang can improve the clinical symptoms and the mechanism of action in patients with peptic ulcer may be related to the inhibition of gastric acid and gastrin over-secretion and increase the secretion of somatostatin in peptic ulcer patients. The prescription has a certain degree of clinical promotion value.